Omeros Corporation
25 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN (NCT06209736) | Omeros Corporation | 2024-03-01 |
| Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria (NCT06298955) | Omeros Corporation | 2024-02-19 |
| Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA (NCT05855083) | Omeros Corporation | 2023-05-01 |
| Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab (NCT05972967) | Omeros Corporation | 2023-03-27 |
| Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT05889299) | Omeros Corporation | 2022-12-09 |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (NCT03205995) | Omeros Corporation | 2018-05-02 |
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (NCT03608033) | Omeros Corporation | 2018-04-05 |
Track Omeros Corporation automatically
Every clearance here is in the API, with alerts when new ones post.